Q1 2018 Earnings Estimate for Cambrex Corporation Issued By First Analysis (NYSE:CBM)
Cambrex Corporation (NYSE:CBM) – Equities research analysts at First Analysis lifted their Q1 2018 earnings per share estimates for shares of Cambrex Corporation in a report issued on Monday. First Analysis analyst S. Schwartz now forecasts that the biotechnology company will post earnings of $0.63 per share for the quarter, up from their previous estimate of $0.58. First Analysis also issued estimates for Cambrex Corporation’s Q2 2018 earnings at $0.87 EPS.
Cambrex Corporation (NYSE:CBM) last released its quarterly earnings results on Friday, August 4th. The biotechnology company reported $0.76 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.76. Cambrex Corporation had a return on equity of 24.25% and a net margin of 17.70%. The firm had revenue of $134.55 million during the quarter, compared to the consensus estimate of $136.82 million. During the same quarter in the prior year, the firm posted $0.68 EPS. The business’s revenue was up 13.4% on a year-over-year basis. COPYRIGHT VIOLATION WARNING: “Q1 2018 Earnings Estimate for Cambrex Corporation Issued By First Analysis (NYSE:CBM)” was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2017/08/08/q1-2018-earnings-estimate-for-cambrex-corporation-issued-by-first-analysis-nysecbm.html.
CBM has been the topic of several other research reports. Zacks Investment Research raised Cambrex Corporation from a “hold” rating to a “buy” rating and set a $59.00 target price on the stock in a research report on Thursday, May 11th. BidaskClub raised Cambrex Corporation from a “sell” rating to a “hold” rating in a research report on Saturday, June 10th. Finally, ValuEngine cut Cambrex Corporation from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $64.00.
Cambrex Corporation (NYSE:CBM) traded up 2.73% during trading on Tuesday, reaching $56.35. The company’s stock had a trading volume of 90,854 shares. The company’s 50-day moving average is $58.97 and its 200-day moving average is $55.37. Cambrex Corporation has a 12 month low of $38.30 and a 12 month high of $62.95. The stock has a market cap of $1.84 billion, a PE ratio of 21.45 and a beta of 2.28.
In related news, Director Leon J. Hendrix, Jr. sold 20,656 shares of Cambrex Corporation stock in a transaction on Tuesday, June 6th. The stock was sold at an average price of $55.95, for a total transaction of $1,155,703.20. Following the sale, the director now directly owns 74,662 shares in the company, valued at $4,177,338.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Steven M. Klosk sold 12,000 shares of Cambrex Corporation stock in a transaction on Thursday, June 1st. The stock was sold at an average price of $54.19, for a total value of $650,280.00. Following the sale, the chief executive officer now owns 95,328 shares in the company, valued at $5,165,824.32. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 70,656 shares of company stock worth $4,064,423. 2.48% of the stock is owned by insiders.
A number of hedge funds have recently modified their holdings of the company. Nisa Investment Advisors LLC raised its stake in shares of Cambrex Corporation by 9.3% in the second quarter. Nisa Investment Advisors LLC now owns 1,760 shares of the biotechnology company’s stock worth $105,000 after buying an additional 150 shares during the period. Creative Planning raised its stake in shares of Cambrex Corporation by 162.6% in the second quarter. Creative Planning now owns 1,765 shares of the biotechnology company’s stock worth $105,000 after buying an additional 1,093 shares during the period. Flinton Capital Management LLC raised its stake in shares of Cambrex Corporation by 3.8% in the first quarter. Flinton Capital Management LLC now owns 1,870 shares of the biotechnology company’s stock worth $103,000 after buying an additional 68 shares during the period. YorkBridge Wealth Partners LLC raised its stake in shares of Cambrex Corporation by 20.2% in the first quarter. YorkBridge Wealth Partners LLC now owns 1,874 shares of the biotechnology company’s stock worth $106,000 after buying an additional 315 shares during the period. Finally, Meeder Asset Management Inc. acquired a new stake in shares of Cambrex Corporation during the first quarter worth approximately $109,000. Institutional investors and hedge funds own 98.28% of the company’s stock.
Cambrex Corporation Company Profile
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Receive News & Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.